Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 28, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the registrant.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of specific share transactions rather than a financial performance report.
Material Changes
The filing details a change in the number of Ordinary Share ADRs held by the GlaxoSmithKline US Retirement Savings Plan ("the Plan").
- Date of Movement: July 27, 2006
- Previous Holding: 17,339,151 ADRs
- New Holding: 17,298,647 ADRs
- Average Price: $54.91
- Reason: A movement in the fund.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It notes that the Plan is a discretionary fund for employees and former employees. Two directors, Dr. J P Garnier and Dr. M M Slaoui, are potentially interested in the shares held in the fund in the same manner as other employees.
Key Facts for Investor Verification
- The reduction in ADR holdings (40,504 shares) was driven by fund movements within the US Retirement Savings Plan, not necessarily direct sales by directors.
- Directors Dr. J P Garnier and Dr. M M Slaoui have potential interests in the fund but are not explicitly stated to have executed direct trades in this specific notification.
- The transaction was notified under Disclosure Rule 3.1.4R(1)(b).